Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, multi-center, single-blind, within-subject, placebo-controlled study to assess the pharmacodynamics of ACT-709478 in subjects with photosensitive epilepsy

Next Previous
X
Search
Trial Profile

A Phase 2a, multi-center, single-blind, within-subject, placebo-controlled study to assess the pharmacodynamics of ACT-709478 in subjects with photosensitive epilepsy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apinocaltamide (Primary)
  • Indications Reflex epilepsy
  • Focus Pharmacodynamics
  • Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals

    • Most Recent Events

    • 25 Jul 2018 Status changed from recruiting to completed.
    • 07 Nov 2017 Status changed from not yet recruiting to recruiting.
    • 25 Oct 2017 Planned initiation date changed from 9 Oct 2017 to 14 Nov 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top